Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancer

A compound chosen from compounds of formula (Ia') or pharmaceutically acceptable salts or solvates thereof:

• wherein:
• RX comprises a chelator;
• n is 1;
• m is 1, 2, 3, or 4;
• X is naphthyl, phenyl, biphenyl, indolyl (=2,3-benzopyrrolyl), or benzothiazolyl;
• each Y is independently aryl, alkylaryl, cyclopentyl, cyclohexyl, or cycloheptyl;
• and
• each Z is independently —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H, or —PO4H2.

A composition comprising:

• (a) a compound chosen from compounds of formula (la') or pharmaceutically acceptable salts or solvates thereof:
• wherein:
• RX comprises a chelator;
• n is 1;
• m is 1, 2, 3, or 4;
• X is naphthyl, phenyl, biphenyl, indolyl (=2,3-benzopyrrolyl), or benzothiazolyl;
• each Y is independently aryl, alkylaryl, cyclopentyl, cyclohexyl, or cycloheptyl;
• and
• each Z is independently —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H, or —PO4H2;
• and
• (b) a pharmaceutically acceptable carrier.

A metal complex comprising a compound chosen from compounds of formula (Ia') or pharmaceutically acceptable salts or solvates thereof:

• wherein:
• RX comprises a chelator;
• n is 1;
• m is 1, 2, 3, or 4;
• X is naphthyl, phenyl, biphenyl, indolyl (=2,3-benzopyrrolyl), or benzothiazolyl;
• each Y is independently aryl, alkylaryl, cyclopentyl, cyclohexyl, or cycloheptyl;
• each Z is independently —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H, or —PO4H2;
• and
• a radionuclide is complexed to the chelator.